PYLARIFY Becomes First Blockbuster Radiodiagnostic with $1.06 Billion in 2024 Sales
核心洞察
PYLARIFY, a fluorinated PSMA (搜索)-targeted PET imaging agent, achieved $1.058 billion in 2024 sales with 24.3% growth, becoming the first radiodiagnostic to reach blockbuster status.
PLUVICTO, a lutetium-177-based radioligand therapy targeting PSMA (搜索)-positive metastatic castration-resistant prostate cancer, generated $1.392 billion in 2024 sales with 42% growth.
The PSMA (搜索)-targeted therapy and radiodiagnostics market demonstrates strong commercial validation, with key opportunities in radioligand therapy expansion and PSMA-targeted PET imaging for prostate cancer.
The PSMA (搜索)-targeted therapy and radiodiagnostics market has achieved a historic milestone as PYLARIFY becomes the first radiodiagnostic agent to surpass $1 billion in annual sales, according to a new competitive intelligence report released by ResearchAndMarkets.com.
PYLARIFY Achieves Blockbuster Status
PYLARIFY, a fluorinated PSMA (搜索)-targeted PET imaging agent, generated $1.058 billion in net sales during 2024, representing a 24.3% increase compared to 2023. This achievement marks the first time a radiodiagnostic has reached blockbuster status, defined as exceeding $1 billion in annual sales.
The success of PYLARIFY demonstrates the clinical validation and commercial viability of PSMA (搜索)-targeting as an approach for positron emission tomography (PET) imaging in prostate cancer diagnosis and monitoring.
PLUVICTO Demonstrates Strong Therapeutic Performance
Alongside the diagnostic success, PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) continues to show robust commercial performance in the therapeutic space. The radioligand therapeutic agent posted 2024 sales of $1.392 billion, representing a 42% increase versus 2023.
PLUVICTO is a PSMA (搜索)-binding ligand bound to a DOTA chelator radiolabeled with lutetium-177, specifically designed for treatment of PSMA-positive metastatic castration-resistant prostate cancer. The strong sales growth reflects the expanding adoption of radioligand therapy in advanced prostate cancer treatment.
Market Opportunities and Clinical Validation
The competitive intelligence report highlights that PSMA (搜索)-targeting represents a clinically validated and increasingly commercially successful approach for both diagnostic imaging and therapeutic intervention in prostate cancer. The main market opportunities lie in the commercialization and development of PSMA-targeted therapies and radiodiagnostics for prostate cancer.
Key areas for expansion include radioligand therapy and PSMA (搜索)-targeted PET imaging, leveraging PSMA's role in targeting prostate cancer with innovative payloads. The report provides a competitor evaluation in the field of product candidates in research and development targeting prostate-specific membrane antigen (PSMA), listing PSMA-targeted R&D programs by development phase and describing the profile of PSMA-targeted therapies or radiodiagnostics by drug modality.